RxDoctor Payments Data

Philip Kuo, MD

Allergy & Immunology · Kailua, HINPI 1164459327

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (58.6%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. GE HealthCare accounts for 68.0% of it on its own, with 26 other manufacturers making up the rest. Reporting peaked in 2024 at $19,859 and has fallen 94.1% since, to $1,173 in 2025.

$27,310in general payments, 2019–2025

Across 389 payments — averaging $70.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GE HealthCare$19K
  • GSK$3K
  • AstraZeneca$2K
  • Regeneron Healthcare Solutions, Inc.$2K
  • Sanofi$487
  • Genentech USA, Inc.$413
  • plus $1K from 21 others
$814in research payments, 2019–2025

Across 2 payments — averaging $407.05 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Novartis Pharma AG$814

What the payments were for

  • Consulting fees$1,4505%
  • Speaking & faculty fees$16,01659%
  • Travel & lodging$1,1154%
  • Food & beverage$8,72932%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few allergy & immunology providers in Hawaiito place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$81,730
Medicare patients
193
Services billed
5,641

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter19$21,826
Azelastine Hcl45$2,087
Albuterol Sulfate HfaAlbuterol Sulfate29$871
Fluticasone Propionate38$739
Proair RespiclickAlbuterol Sulfate11$732
Triamcinolone Acetonide28$252
Montelukast Sodium11$223
Prednisone21$77

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta$2,574$21,82619 claims
Teva Pharmaceuticals USA, Inc.Proair Respiclick$20$73211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few allergy & immunology providers in Hawaiion file to place this against a meaningful peer group, so we don't.

Other allergy & immunology in Kailua

See the full list for Hawaii

Where these figures come from

Is this you, or does something look wrong? →